Haemonetics 4th Quarter Fiscal Year 2021 Earnings Release Available on Investor Relations Website
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Haemonetics (HAE) PT Lowered to $86 at Needham & Company
May 13, 2021 1:03 PM EDTNeedham & Company analyst Mike Matson lowered the price target on Haemonetics (NYSE: HAE) to $86.00 (from $108.00) while maintaining a Buy rating.
The analyst commented, "HAE's F4Q21 revenue beat and EPS missed consensus. HAE's organic growth slowed to (13.7%) in F4Q21 vs. (5.7%)... More
Haemonetics (HAE) Misses Q4 EPS by 21c, Revenues Beat; Offers FY22 EPS Guidance Above Consensus
May 13, 2021 6:07 AM EDTHaemonetics (NYSE: HAE) reported Q4 EPS of $0.46, $0.21 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $225 million versus the consensus estimate of $222.98 million.
